Grody E.I.*, Abraham A.*, Shukla V.#, Goyal Y.# Toward a systems-level probing of tumor clonality. iScience 2023, PMID: 37192968 *co-first authors, # co-corresponding authors
Wu L., Shukla V., Yadavalli AD, Dinesh RK, Xu D., Rao A., Schatz DG. HMCES protects immunoglobulin genes specifically from deletions during somatic hypermutation. Genes and Development, Genes and Development 2022, PMID:35450882.
Shukla V.*, Samaniego-Castruita D.*, Dong Z., González-Avalos E., Yan Q., Sarma K., Rao A. TET deficiency perturbs mature B cell homeostasis and is associated with accumulation of G-quadruplex and R-loop structures during oncogenesis. Nature Immunology, January 2022, PMID: 34937926. *co-first authors
Shukla V., Halabelian L., Balagere S.V., Samaniego-Castruita D., Feldman D.E., Arrowsmith C.H.#, Rao A. #, Aravind L#. A novel role of HMCES in the regulation of alternative end joining pathway during class switch recombination in B cells. Mol Cell. 2020 Jan 16;77(2):384-394.e4. doi: 10.1016/j.molcel.2019.10.031. Epub 2019 Dec 2. PubMed PMID: 31806351.
#co-corresponding authors
Lio C-WJ. *, Shukla V.*, Samaniego-Castruita D., González-Avalos E., Chakraborty A., Yue X., Schatz DG, Ay F., Rao A. TET enzymes augment AID expression via 5hmC modifications at the Aicda superenhancer. Sci Immunol. 2019 Apr 26;4(34). doi: 10.1126/sciimmunol.aau7523. PubMed PMID: 31028100.
*co-first authors
A Shukla, V Shukla, SS Joshi. Regulation of MAPK signaling and implications in chronic lymphocytic leukemia. Leuk Lymphoma. 2018 Jul;59(7):1565-1573. doi: 10.1080/10428194.2017.1370548. Epub 2017 Sep 7. Review. PubMed PMID: 28882083
Shukla V.*, Shukla A., Joshi SS, Lu R. Interferon Regulatory Factor 4 attenuates Notch signaling to suppress the development of CLL. Oncotarget. 2016 Jul 5;7(27):41081-41094. doi: 10.18632/oncotarget.9596. PubMed PMID: 27232759.
*Corresponding author.
Shukla V.*, Lu R*. (Review). IRF4 and IRF8: Governing the virtues of B lymphocytes. Front Biol. 2014 Aug;9(4):269-282. doi: 10.1007/s11515-014-1318-y. PubMed PMID: 25506356.
*co-corresponding authors
Haney SL, Upchurch GM, Opavska J, Klinkebiel D, Hlady RA, Suresh A, Pirruccello SJ, Shukla V., Lu R, Costinean S, Rizzino A, Karpf AR, Joshi S, Swanson P, Opavsky R. Promoter Hypomethylation and Expression Is Conserved in Mouse Chronic Lymphocytic Leukemia Induced by Decreased or Inactivated Dnmt3a. Cell Rep. 2016 May 10;15(6):1190-201. doi: 10.1016/j.celrep.2016.04.004. Epub 2016 Apr 28. PubMed PMID: 27134162.
Shukla A, Rai KJ, Shukla V., Chaturvedi NK, Bociek GR, Pirrulcello SJ, Band H, Lu R, Joshi SS. Sprouty 2: a novel attenuator for B-cell receptor and MAPK-Erk Signaling in CLL. Blood. 2016 May 12;127(19):2310-21. doi: 10.1182/blood-2015-09-669317. Epub 2016 Jan 25. PubMed PMID: 26809508.
Pathak S, Ma S, Shukla V., Lu R. A role for IRF8 in B cell anergy. J Immunol. 2013 Dec 15;191(12):6222-30. doi: 10.4049/jimmunol.1301169. Epub 2013 Nov 11. PubMed PMID: 24218455.
Shukla V*, Ma S*, Hardy RR, Joshi SS, Lu R. A role for IRF4 in the development of CLL. Blood. 2013 Oct 17;122(16):2848-55. doi: 10.1182/blood-2013-03-492769. Epub 2013 Aug 7. PubMed PMID: 23926303.
*co-first authors.
Commentary by Dr. John C. Byrd a leading expert in the field of hematology, in “IRF4(-/- )Vh11 mice: a novel mouse model of CLL”, Blood 2013; 122: 2769-70.
Ma S *, Shukla V*, Fang L, Gould KA, Joshi SS, Lu R. Accelerated development of CLL in NZB mice expressing low levels of IRF4. J Biol Chem. 2013 Sep 13;288(37):26430-40. doi: 10.1074/jbc.M113.475913. Epub 2013 Jul 29. PubMed PMID: 23897826
*co-first authors.
Highlighted in “IRF4-deficient mouse models of CLL”, SciBX (Nature Publishing Group) Oct 2013 SciBX 6; doi:10.1038/scibx.2013.1076.